Literature DB >> 2864845

Effects of esmolol on cardiac function: evaluation by noninvasive techniques.

A S Iskandrian, A H Hakki, A Laddu.   

Abstract

In a double-blind, randomized, crossover study, the effects of esmolol and propranolol were examined at rest and during peak upright exercise in 15 patients. At rest, both esmolol and propranolol significantly decreased heart rate, systolic blood pressure, rate-pressure product, left ventricular ejection fraction, cardiac index and right ventricular ejection fraction. During exercise, significant decreases were also found in heart rate, systolic blood pressure and cardiac index in both treatment groups. No significant differences were found between mean esmolol and mean propranolol measurements at rest and during exercise, except for the exercise systolic blood pressure, which was lower during esmolol infusion. Blood levels of esmolol decreased markedly by 30 minutes postinfusion, as did its beta-blocking action. Esmolol was well tolerated with no important local, systemic or laboratory abnormalities. Thus, the effects of esmolol on cardiovascular performance at rest and during exercise are similar to those of propranolol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864845     DOI: 10.1016/0002-9149(85)90913-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  β1-Blockade increases maximal apnea duration in elite breath-hold divers.

Authors:  Ryan L Hoiland; Philip N Ainslie; Anthony R Bain; David B MacLeod; Mike Stembridge; Ivan Drvis; Dennis Madden; Otto Barak; Douglas M MacLeod; Zeljko Dujic
Journal:  J Appl Physiol (1985)       Date:  2016-04-28

Review 2.  Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P Benfield; E M Sorkin
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

3.  Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.

Authors:  B F Cuneo; V R Zales; P C Blahunka; D W Benson
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

4.  Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.

Authors:  C Volz-Zang; B Eckrich; P Jahn; B Schneidrowski; B Schulte; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.